<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-9933</journal-id>
<journal-title><![CDATA[Revista Información Científica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. inf. cient.]]></abbrev-journal-title>
<issn>1028-9933</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas Guantánamo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-99332023000100026</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Ácido valproico y ganancia de peso en pacientes con tratamiento antiepiléptico: una revisión sistemática]]></article-title>
<article-title xml:lang="en"><![CDATA[Valproic acid and weight gain in patients receiving antiepileptic treatment: a systematic review]]></article-title>
<article-title xml:lang="pt"><![CDATA[Ácido valpróico e ganho de peso em pacientes recebendo tratamento antiepiléptico: uma revisão sistemática]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torlasco]]></surname>
<given-names><![CDATA[María Belén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estrin]]></surname>
<given-names><![CDATA[Marcelo Adrián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Abierta Interamericana Facultad de Medicina y Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Argentina</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>102</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-99332023000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-99332023000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-99332023000100026&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El ácido valproico es un fármaco que se utiliza en el tratamiento de varias enfermedades, entre ellas la epilepsia. Aunque se lo considera un fármaco seguro presenta distintos efectos adversos entre ellos el más común es el aumento considerable de peso corporal.  Objetivo:  Identificar la relación entre el uso de ácido valproico en pacientes con tratamiento antiepiléptico y la ganancia de peso.  Método:  Revisión sistemática realizada en la Universidad Abierta Interamericana, en la que se realizó una búsqueda exhaustiva de estudios en la base de datos PubMed con términos MesH sobre Valproic acid AND weight gain. Una vez seleccionados los artículos tras la aplicación de criterios de inclusión y exclusión quedaron 17, los que fueron útiles para llevar a cabo esta investigación.  Resultados:  La información de los artículos hallados revela que los mecanismos a través del cual el ácido valproico puede generar este incremento de peso corporal aún no están del todo esclarecidos. Se han propuesto varias hipótesis; las más frecuentes en la literatura son: la hiperinsulinemia y resistencia a la insulina, así como también la hiperleptinemia y la resistencia a la leptina, entre otros. Los pacientes que presentan ganancia de peso tienen importantes consecuencias para la salud, en particular, el desarrollo de obesidad y la asociación con dislipidemia, hipertensión arterial, diabetes mellitus tipo 2 y aterosclerosis. Además, al generar cambios en la imagen corporal puede traer aparejada depresión, disminución de la autoestima y confianza en sí mismo, lo que provoca el incumplimiento y abandono del tratamiento.  Conclusiones:  Se observa la relación de causalidad del ácido valproico sobre la ganancia de peso en pacientes que padecen epilepsia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Valproic acid is a drug used in the treatment of various diseases, including epilepsy. Although it is considered a safe drug, it presents different adverse effects, among them the most common is the considerable increase in body weight.  Objective:  To identify the relationship between the use of valproic acid in patients with antiepileptic treatment and weight gain.  Method:  Systematic review carried out at the Universidad Abierta Interamericana, Argentina, in which an exhaustive search of studies was carried out in the PubMed database with MeSH terms on Valproic acid AND weight gain. Once the articles were selected after applying the inclusion and exclusion criteria, 17 remained, which were useful to carry out this research.  Results:  The information from the articles found reveals that the mechanisms through which valproic acid can generate this increase in body weight are still not fully clarified. Several hypotheses have been proposed; the most frequent in the literature are: hyperinsulinemia and insulin resistance, as well as hyperleptinemia and leptin resistance, among others. Patients who present weight gain have important health consequences, particularly the development of obesity and the association with dyslipidemia, arterial hypertension, type 2 diabetes mellitus, and atherosclerosis. In addition, by generating changes in body image, it can bring depression, decreased self-esteem and self-confidence, which causes non-compliance and abandonment of treatment.  Conclusions:  The causal relationship of valproic acid on weight gain in patients with epilepsy is observed.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  O ácido valpróico é um fármaco utilizado no tratamento de diversas doenças, entre elas a epilepsia. Apesar de ser considerado um medicamento seguro, apresenta diversos efeitos adversos, dentre eles o mais comum é o aumento considerável do peso corporal.  Objetivo:  Identificar a relação entre o uso de ácido valpróico em pacientes em tratamento antiepiléptico e o ganho de peso.  Método:  Revisão sistemática realizada na Universidad Abierta Interamericana, na qual foi realizada uma busca exaustiva de estudos na base de dados PubMed com termos MeSH sobre ácido valpróico AND ganho de peso. Uma vez selecionados os artigos após a aplicação dos critérios de inclusão e exclusão, restaram 17, que foram úteis para a realização desta pesquisa.  Resultados:  As informações dos artigos encontrados revelam que os mecanismos pelos quais o ácido valpróico pode gerar esse aumento de peso corporal ainda não estão totalmente esclarecidos. Várias hipóteses foram propostas; os mais frequentes na literatura são: hiperinsulinemia e resistência à insulina, assim como hiperleptinemia e resistência à leptina, entre outros. Pacientes que apresentam ganho de peso trazem importantes consequências para a saúde, principalmente o desenvolvimento de obesidade e associação com dislipidemia, hipertensão arterial, diabetes mellitus tipo 2 e aterosclerose. Além disso, por gerar alterações na imagem corporal, pode trazer depressão, diminuição da autoestima e da autoconfiança, o que ocasiona a não adesão e abandono do tratamento.  Conclusões:  Observa-se a relação causal do ácido valpróico com o ganho de peso em pacientes com epilepsia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[antiepilépticos]]></kwd>
<kwd lng="es"><![CDATA[ácido valproico]]></kwd>
<kwd lng="es"><![CDATA[ganancia de peso]]></kwd>
<kwd lng="es"><![CDATA[leptina]]></kwd>
<kwd lng="es"><![CDATA[insulina]]></kwd>
<kwd lng="en"><![CDATA[antiepileptics]]></kwd>
<kwd lng="en"><![CDATA[valproic acid]]></kwd>
<kwd lng="en"><![CDATA[weight gain]]></kwd>
<kwd lng="en"><![CDATA[leptin]]></kwd>
<kwd lng="en"><![CDATA[insulin]]></kwd>
<kwd lng="pt"><![CDATA[antiepilépticos]]></kwd>
<kwd lng="pt"><![CDATA[ácido valpróico]]></kwd>
<kwd lng="pt"><![CDATA[ganho de peso]]></kwd>
<kwd lng="pt"><![CDATA[leptina]]></kwd>
<kwd lng="pt"><![CDATA[insulina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rauchenzauner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haberlandt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Scholl-Bürgi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Karall]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenherr]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tatarczyk]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children]]></article-title>
<source><![CDATA[Epilepsy Res]]></source>
<year>2008</year>
<volume>80</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>142-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Demir]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aysun]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight gain associated with valproate in childhood]]></article-title>
<source><![CDATA[Ped Neurol]]></source>
<year>2000</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>361-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perucca]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological and Therapeutic Properties of Valproate: A Summary After 35 Years of Clinical Experience]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2002</year>
<volume>16</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>695-714</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Löscher]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action]]></article-title>
<source><![CDATA[Prog Neurobiol]]></source>
<year>1999</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-59</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Löscher]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain]]></article-title>
<source><![CDATA[Neurochem Res]]></source>
<year>1993</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>485-502</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamed]]></surname>
<given-names><![CDATA[SA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leptin and insulin homeostasis in epilepsy: Relation to weight adverse conditions]]></article-title>
<source><![CDATA[Epilepsy Res]]></source>
<year>2007</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tokgoz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aydin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Oran]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kiyici]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate]]></article-title>
<source><![CDATA[Childs Nerv Syst]]></source>
<year>2012</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1049-53</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wirrell]]></surname>
<given-names><![CDATA[EC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproic acid-associated weight gain in older children and teens with epilepsy]]></article-title>
<source><![CDATA[Ped Neurol]]></source>
<year>2003</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>126-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brett]]></surname>
<given-names><![CDATA[EM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of sodium valproate in 100 children with special reference to weight]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1981</year>
<volume>283</volume>
<numero>6291</numero>
<issue>6291</issue>
<page-range>577-81</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dinesen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gram]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dam]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight gain during treatment with valproate]]></article-title>
<source><![CDATA[Acta Neurol Scand]]></source>
<year>1984</year>
<volume>70</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamed]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Fida]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Hamed]]></surname>
<given-names><![CDATA[EA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[States of serum leptin and insulin in children with epilepsy: Risk predictors of weight gain]]></article-title>
<source><![CDATA[Eur J Paed Neurol]]></source>
<year>2009</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>261-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verrotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[la Torre]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Trotta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mohn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarelli]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproate-Induced Insulin Resistance and Obesity in Children]]></article-title>
<source><![CDATA[Horm Res Paed]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharpe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Trauner]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight Gain in Children Treated With Valproate]]></article-title>
<source><![CDATA[J Child Neurol]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petty]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kantor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Berkovic]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight and fat distribution in patients taking valproate: A valproate-discordant gender-matched twin and sibling pair study]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2014</year>
<volume>55</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1551-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Khatib]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rauchenzauner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lechleitner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hoppichler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Naser]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Waldmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valproate, weight gain and carbohydrate craving: A gender study]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2007</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>226-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biton]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mirza]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Montouris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vuong]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hammer]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[PS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2001</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pylvänen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pakarinen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Knip]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Isojärvi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin-related metabolic changes during treatment with valproate in patients with epilepsy]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2006</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>643-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isojärvi]]></surname>
<given-names><![CDATA[JIT]]></given-names>
</name>
<name>
<surname><![CDATA[Laatikainen]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knip]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pakarinen]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Juntunen]]></surname>
<given-names><![CDATA[KTS]]></given-names>
</name>
<name>
<surname><![CDATA[Myllyla]]></surname>
<given-names><![CDATA[VV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and endocrine disorders in women taking valproate for epilepsy: Valproate and Endocrine Disorders]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1996</year>
<volume>39</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>579-84</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meral]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cekmez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vurucu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tascilar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pirgon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Canpolat]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid]]></article-title>
<source><![CDATA[Eur Cytokine Netw]]></source>
<year>2011</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>118-22</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Latini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Iannetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Verrotti]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2005</year>
<volume>65</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1808-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gungor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yücel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Akinci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tabel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ozerol]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Yologlu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Role of Ghrelin in Weight Gain and Growth in Epileptic Children Using Valproate]]></article-title>
<source><![CDATA[J Child Neurol]]></source>
<year>2007</year>
<volume>22</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1384-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Fok]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Fujii]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro]]></article-title>
<source><![CDATA[J Cell Biochem]]></source>
<year>2005</year>
<volume>96</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>775-85</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luef]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Haslinger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Trinka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Seppi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Unterberger]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polycystic ovaries, obesity and insulin resistance in women with epilepsy]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2002</year>
<volume>249</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>835-41</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luef]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hoppichler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Trinka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Unterberger]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>2002</year>
<volume>51</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1274-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrell]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Isojärvi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Dam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy]]></article-title>
<source><![CDATA[Epilepsy Res]]></source>
<year>2003</year>
<volume>54</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>189-99</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verrotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Latini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Simone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chiarelli]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and Plasma Concentrations of Alpha-Tocopherol and Beta-Carotene in Epileptic Girls Treated with Valproate]]></article-title>
<source><![CDATA[Neuroendocrinol]]></source>
<year>2004</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>157-62</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aydin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Serdaroglu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Okuyaz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bideci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gucuyener]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum Insulin, Leptin, and Neuropeptide Y Levels in Epileptic Children Treated With Valproate]]></article-title>
<source><![CDATA[J Child Neurol]]></source>
<year>2005</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>848-51</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pylvänen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pakarinen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Knip]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Isojärvi]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of Insulin Secretion in Valproate-treated Patients with Epilepsy]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2006</year>
<volume>47</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1460-4</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rauchenzauner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haberlandt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Scholl-Bürgi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hoppichler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Karall]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adiponectin and visfatin concentrations in children treated with valproic acid]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2008</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>353-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grosso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mostardini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Piccini]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Balestri]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Body Mass Index and Serum Lipid Changes During Treatment with Valproic Acid in Children with Epilepsy]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2009</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-50</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cansu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Serdaroglu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Çamurdan]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hirfanoglu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cinaz]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum Insulin, Cortisol, Leptin, Neuropeptide Y, Galanin and Ghrelin Levels in Epileptic Children Receiving Valproate]]></article-title>
<source><![CDATA[Horm Res Paed]]></source>
<year>2011</year>
<volume>76</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-71</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
